Imagine you're organizing a library, but your labeling system thinks every book is about the same thing. You ask it: is this chemistry textbook related to this romance novel? It says yes — 83% confident. Not because it found a connection, but because its distance metric is broken. Every book in the building is equidistant from every other book, which means the labels are useless for deciding what goes on which shelf. That's the state of biomedical sentence embeddings when you use them outside retrieval. Cosine similarity between "cortisol 28 ug/dL" and "stock-market volatility" comes back 0.83. Cross-domain discrimination accuracy: literally 0%. The committed claim: pretrained biomedical encoders (BioBERT, PubMedBERT, BioM-ELECTRA) are geometrically broken for causal reasoning — they cannot separate within-domain similarity from cross-domain noise — and a two-stage contrastive fix (domain-aware fine-tuning plus knowledge-graph-mined hard negatives called BODHI) repairs the geometry enough to serve as the embedding layer for Large Behavioural Models. This is not the Nth contrastive-learning paper. The novelty is the failure mode they expose and the specific downstream it matters for: LBMs that treat embedding proximity as causal evidence. The ladder is honest and specific. Baseline PubMedBERT scores 0.633 on BIOSSES correlation with a within-vs-across-domain separation of just 1.05× — barely above chance. Their contrastive pass lifts BIOSSES to 0.828 and separation to 1.63×. BODHI, the hard-negative stage, pushes separation to 2.30× and the discrimination gap to +0.392, at a 4.5% cost to BIOSSES. They don't claim to beat PubMedBERT on standard semantic similarity — they trade a small regression on the community benchmark for a massive gain on the metric that actually matters for their use case. That's the right tradeoff to name. Architecturally, this is contrastive fine-tuning in the SimCLR/CLIP family, applied to transformer encoders (PubMedBERT-base), with a two-phase curriculum: first supervised contrastive on 72,034 curated pairs, then knowledge-graph-mined hard negatives (BODHI) drawn from edges absent in a biomedical KG. The hardware story is unusually detailed. On an Intel Xeon 6737P with AMX instructions, OpenVINO cuts single-query latency from 1,367 ms to 10 ms — a 133× speedup — reaching 555 sentences/sec. One counterintuitive finding: FP16 beats INT8 at every batch size on this silicon, contradicting standard quantization advice. The same model on no-AMX Ice Lake hardware runs 13–27× slower. They explicitly name the hardware dependency, which most papers hide. Integrity is mixed. BIOSSES is a community benchmark, which is good. But the cross-domain discrimination task is their own benchmark, purpose-built for this paper. That's not circular — the failure mode they expose is real and easily reproducible — but it means the headline metric (2.30× separation) hasn't been validated by anyone else yet. They release the benchmark suite, training corpora, the BODHI generator, and the OpenVINO scripts, which is the right move. No pre-registration. The 4.5% BIOSSES regression is honestly reported, not buried. The milestone that matters: 2.30× domain separation is where LBM causal graphs stop hallucinating edges between unrelated life domains. The next number is probably 5× separation with zero BIOSSES regression — the point where you can drop BODHI-tuned embeddings into a production LBM pipeline without any downstream quality loss. That's likely 1–2 years out, contingent on larger KG-mined training sets and multi-encoder architectures. The obvious experiment they didn't run: plugging these embeddings into an actual LBM and measuring end-to-end causal graph accuracy. They describe the LBM motivation extensively but never test against one. Honest read: the LBM infrastructure isn't ready, or the team building the LBM is a different group and the integration hasn't happened yet. This paper ships the embedding fix; the integration paper is next.